September 22, 2023
FDA approves Krystal Biotech’s KB408 for AATD treatment
The US Food and Drug Administration (FDA) has granted clearance to Krystal Biotech’s investigational new drug application (IND) for KB408 to treat alpha-1 antitrypsin deficiency (AATD), a rare genetic disease.